Nova Eye Medical (AU:EYE) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Nova Eye Medical Limited reports a significant upswing in FY24 with group sales rising 35% to A$23.3 million, driven by a robust 71% surge in the US market. The company’s EBITDA loss improved by 33%, indicating a promising trend towards profitability, especially in its glaucoma segment. Additionally, the company anticipates further sales growth from proposed Medicare reimbursement rate increases for its products in the USA.
For further insights into AU:EYE stock, check out TipRanks’ Stock Analysis page.
